CA-AIRSPACE-TECH
10.12.2020 14:02:12 CET | Business Wire | Press release
Airspace Technologies, Inc. (Airspace), the company revolutionizing air cargo and time-critical logistics, has opened its first European office, with the launch of Airspace B.V. From the headquarters, located at Schiphol-Rijk, the Netherlands, which opened in June this year, Airspace will be expanding its team across the Netherlands, France, Germany, and the U.K., in line with its rapid growth plans to fulfill customer demand.
Airspace’s technology is transforming and modernizing the logistics industry. Their proprietary software uses machine learning to identify the fastest and lowest risk path out of millions of possibilities. The technology proactively ensures that any potential delays are avoided and guarantees the customer real-time, end-to-end visibility. While officials anticipate significant problems at the borders due to Brexit, Airspace’s technology will greatly reduce the impact of the logistics issues for the customer and allow vital products and services to still be delivered on time.
The new European operation will be managed by Marcel Andriessen, who has successfully led logistics companies specializing in worldwide time-critical services over the last 20 years. Andriessen was the Managing Director at time:matters for 10 years and was responsible for the success of their European business and the expansion into the U.S. Andriessen will lead the Airspace BV organization as Managing Director.
“I am looking forward to getting back into time-critical logistics and to bring Airspace’s leading-edge technology to the European market. Customers here have not experienced the speed and transparency that Airspace offers, and I welcome the opportunity to show them how much better time-critical logistics can be,” said Andriessen.
The company’s expansion is in response to the demand from global customers who want to further leverage the Airspace technology for their European operations. Industry-leading customers including Quest Diagnostics, Varian Medical, and Allegiant Air Corporation, already rely on Airspace’s proprietary logistics technology and robust delivery network to deliver their mission-critical shipments as fast as possible throughout North America and Europe. They rely on the technology platform Airspace has developed to provide real-time, door-to-door transparency throughout the entire shipment process. This is most important for life-saving industries, such as the medical profession, which depend on rapid deliveries.
“The time-critical market is full of difficult problems. Customers too often have a poor experience because the industry is trying to solve these problems using antiquated practices. Shippers across Europe need a modern platform that can provide the level of transparency and error prevention that these critical shipments deserve,” said Nick Bulcao, Co-Founder & CEO of Airspace Technologies, Inc.
About Airspace Technologies, Inc.
Based in Carlsbad, Calif., Airspace Technologies, Inc. was founded in 2015 and has grown to be the most trusted leader in time-critical logistics. Airspace makes shipping faster, safer, and more transparent than ever through people, service, and technology. From real-time, data-driven notifications to tracking over 16,000 touchpoints within a shipment, Airspace surfaces more information than any other provider, increasing the velocity and transparency of the supply chain.
To learn more about Airspace, please visit www.airspacetechnologies.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201210005537/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom